Amyris, a leading synthetic biotechnology company, has agreed to exclusive terms to acquire the assets of MenoLabs, a women-founded company, to treat menopause symptoms and drive research for women's health.
WHO: MenoLabs, founded by Danielle Jacobs, Vanessa Ford, and John P. Konhilas, PhD, an Associate Professor with the Department of Physiology and Sarver Molecular Cardiovascular Research at the University of Arizona, is focused on addressing perimenopause and menopause symptoms. Over the past two years, MenoLabs has developed and launched eight research-backed all-natural treatment products. The brand also launched MenoLife, a highly rated perimenopause and menopause health tracker app that helps users track and analyze more than 40 menopause-related symptoms.
Amyris is a science and technology leader in the research, development, and production of sustainable ingredients for the Clean Health and Beauty and Flavors & Fragrances markets. Amyris uses an array of exclusive technologies, including state-of-the-art machine learning, robotics, and artificial intelligence. Their portfolio of consumer brands includes Biossance, Pipette, Rose Inc., JVN, Terasana, and Olika.
WHY: Amyris previously communicated its intention of launching a new consumer brand to provide science-backed wellness and personal care products for the high-growth menopause market in 2022. The acquisition of MenoLabs will serve as a catalyst to accelerate growth and establish a leadership position in the fast-growing menopause market.
IN THEIR OWN WORDS: "We are very impressed with the MenoLabs offering which is synergistic with our science-based approach to real-world health and wellness issues. We are committed to empowering women and creating a platform to support them with our leading science and wellness technology platform. Women deserve products and solutions that work during this period in their lives," said John Melo, President and Chief Executive Officer of Amyris. "Our acquisition of the products and app that the MenoLabs team has built accelerates Amyris' entry into the menopause market. We expect the combination of MenoLabs and the previously announced menopause brand with Naomi Watts to have the potential to deliver an estimated $30 million in revenue in their first year and expect significant growth potential in the years ahead. We continue to execute on our growth strategy diversifying our consumer offering in Clean Beauty, Health and Wellness end-markets, continuing the strong growth momentum from 2021 into the current quarter."
DETAILS:
